Pharmacovigilance of Integrase Strand Transfer Inhibitors (INSTIs) in Botswana: Safety Signals, Report Completeness, and Causality Assessment
- 1University of Birmingham
Abstract
Integrase strand transfer inhibitors (INSTIs) are the preferred first-line anchor drug for antiretroviral therapy globally. However, post-marketing authorisation studies continue to find previously unidentified adverse events (AEs) associated with INSTIs. A pharmacovigilance study was conducted to investigate AEs associated with INSTIs submitted to the Botswana national pharmacovigilance database (BoMRA).
All suspected AE reports in which INSTIs were identified as the primary suspect were included for analysis. Descriptive analysis was used to characterise the AEs, and disproportionality analysis was used for signal detection. Causality assessment was conducted using the World Health Organization-Uppsala Monitoring Centre system, the Liverpool ADR Causality Assessment Tool, and the Naranjo Causality Assessment algorithm. Agreement between the methods was assessed through the Cohens Kappa ({kappa}) test.
A total of n = 112 AE reports were reported for cabotegravir and dolutegravir as the primary suspect drugs. Most reports involved females and adults, while dolutegravir was associated with the majority (78.6%). Skin and subcutaneous AEs (25.0%) and rash (10.7%) were the most frequently reported AEs at the system organ class (SOC) and reported preferred term (PT) levels, respectively. Reporter qualification influenced report completeness, with nurses submitting reports with the highest median completeness score.
Most reported AEs were consistent with the established safety profiles of cabotegravir and dolutegravir. However, the study identified unlabelled AEs for both cabotegravir and dolutegravir, including decreased libido, hallucination, severe obesity, acquired lipodystrophy, gynecomastia, cheilitis, and hyperpigmentation. These are potential safety signals that warrant further investigation and underscore the importance of national pharmacovigilance data for ongoing post-marketing safety surveillance and for generating local safety data insights.
Related
- Cumulative exposure to integrase inhibitors and metabolic factors as independent predictors of severe hepatic steatosis in people with HIV.
- HIV resistance in patients with virological failure to single tablet regimen: Roles of second generation integrase strand transfer inhibitors (INSTIs)
- Distinct pattern of reported adverse event with SGLT2 inhibitors in heart failure: A pharmacovigilance study using VigiBase data
- A Highly Sensitive and Specific Rapid Lateral Flow Assay for the HIV Integrase Strand Transfer Inhibitors Bictegravir, Cabotegravir, and Dolutegravir.
- Cardiac adverse event signals of Bruton’s tyrosine kinase inhibitors as primary suspect and in co-reported regimens: a large-scale FAERS pharmacovigilance study
BibTeX
@misc{pono2026pharmacovigilance,
title = {{Pharmacovigilance of Integrase Strand Transfer Inhibitors (INSTIs) in Botswana: Safety Signals, Report Completeness, and Causality Assessment}},
author = {P. Pono and V. Cheng and A. M. Jones},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.08.26362506},
url = {https://www.medrxiv.org/content/10.64898/2026.09.08.26362506v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Pharmacovigilance of Integrase Strand Transfer Inhibitors (INSTIs) in Botswana: Safety Signals, Report Completeness, and Causality Assessment
AU - P. Pono
AU - V. Cheng
AU - A. M. Jones
PY - 2026
DA - 2026/09/08
PB - medRxiv
DO - 10.64898/2026.09.08.26362506
UR - https://www.medrxiv.org/content/10.64898/2026.09.08.26362506v1
AB - Integrase strand transfer inhibitors (INSTIs) are the preferred first-line anchor drug for antiretroviral therapy globally. However, post-marketing authorisation studies continue to find previously unidentified adverse events (AEs) associated with INSTIs. A pharmacovigilance study was conducted to investigate AEs associated with INSTIs submitted to the Botswana national pharmacovigilance database (BoMRA). All suspected AE reports in which INSTIs were identified as the primary suspect were included for analysis. Descriptive analysis was used to characterise the AEs, and disproportionality analysis was used for signal detection. Causality assessment was conducted using the World Health Organization-Uppsala Monitoring Centre system, the Liverpool ADR Causality Assessment Tool, and the Naranjo Causality Assessment algorithm. Agreement between the methods was assessed through the Cohens Kappa ({kappa}) test. A total of n = 112 AE reports were reported for cabotegravir and dolutegravir as the primary suspect drugs. Most reports involved females and adults, while dolutegravir was associated with the majority (78.6%). Skin and subcutaneous AEs (25.0%) and rash (10.7%) were the most frequently reported AEs at the system organ class (SOC) and reported preferred term (PT) levels, respectively. Reporter qualification influenced report completeness, with nurses submitting reports with the highest median completeness score. Most reported AEs were consistent with the established safety profiles of cabotegravir and dolutegravir. However, the study identified unlabelled AEs for both cabotegravir and dolutegravir, including decreased libido, hallucination, severe obesity, acquired lipodystrophy, gynecomastia, cheilitis, and hyperpigmentation. These are potential safety signals that warrant further investigation and underscore the importance of national pharmacovigilance data for ongoing post-marketing safety surveillance and for generating local safety data insights.
ER -